SUBA-itraconazole

DRUG5 trials

Sponsors

Halcygen Pharmaceuticals Limited, HedgePath Pharmaceuticals, Inc., St Vincent's Hospital, Sydney, George R Thompson, Anthony Joshua, FRACP

Conditions

Basal Cell Carcinoma in Basal Cell Nevus SyndromeCoccidioidomycosisOnychomycosisOvarian CancerProstate CancerValley Fever

Phase 1

Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

CompletedNCT03513211

St Vincent's Hospital, SydneyProstate Cancer

Start: 2018-08-23End: 2023-10-30Updated: 2023-11-22

Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer

Active, not recruitingNCT05156892

Anthony Joshua, FRACPOvarian Cancer

Start: 2022-09-04End: 2027-01-01Target: 44Updated: 2025-05-15

Phase 2

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

CompletedNCT00791219

Halcygen Pharmaceuticals LimitedOnychomycosis

Start: 2008-11-30End: 2010-12-31Updated: 2020-08-25

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

CompletedNCT02354261

HedgePath Pharmaceuticals, Inc.Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Start: 2015-08-07End: 2019-03-31Updated: 2020-08-05

SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole

WithdrawnNCT04809649

George R ThompsonCoccidioidomycosis, Valley Fever

Start: 2021-05-15End: 2022-09-30Updated: 2021-07-19

Related Papers

Data from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results

2026-03-27

A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.

Journal of Clinical Oncology2021-02-201 citations